Abstract
The development of specific antagonists of cysteinyl leukotrienes (Cys-LTs) has provided therapeutic agents for use in diseases of the respiratory tract by antagonizing the bronchoconstrictive, mucus secretory and inflammatory effects of these leukotrienes [1–8]. Pranlukast (OnonTM, ONO-1078), zafirlukast (AccolateTM, ICI 204,219) and montelukast (SingulairTM, MK 0476) are available on the market as treatment for asthma [1–6]. Further compounds, such as iralukast (CGP 45715A) are in development for this indication [7,8].
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Horwitz RJ, McGill KA, Busse W (1998) The role of leukotriene modifiers in the treat-ment of asthma. Am J Respir Crit Care Med 157: 1363–1371
Holgate ST, Bradding P, Sampson AP (1996) Leukotriene antagonists and synthesis inhibitors: new directions in asthma therapy. J Allergy Clin Immunol 98 (1): 1–13
O’Byrne PM (1997) Leukotrienes in the pathogenesis of asthma. Chest 111 (Suppl 2): 27S–34S
Barnes NC, de Jong B, Miyamoto T (1997) Worldwide clinical experience with the first marketed leukotriene receptor antagonist. Chest 111 (Suppl 2): 52S–60S
Adkins JC, Brogden RN (1998) Zafirlukast. A review of its pharmacology and thera-peutic potential in the management of asthma. Drugs 55 (1): 121–144
Noonan MJ, Chervinsky P, Brandon M, Zhang J, Kundu S, McBurney J, Reiss TF, for the Montelukast Asthma Study Group (1998) Montelukast, a potent leukotriene receptor antagonist, causes dose-related improvements in chronic asthma. Eur Respir J 11: 1232–1239
Capra V, Bolla M, Belloni PA, Mezzetti M, Folco GC, Nicosia S, Rovati GE (1998) Pharmacological characterization of the cys-LT antagonists CGP 45715A (iralukast) and CGP 57698 in human airways in vitro. Br J Pharmacol 123: 590–598
Tittmann UP, Patalano F, Dessanges JF, Huels J, Lockhart A, Dinh-Xuan AT (in preparation) Inhaled iralukast prevents exercise induced asthma: A single-dose study to determine the efficacy and safety of a leukotriene receptor antagonist
Ford-Hutchinson A, Young RN, Gillard J (1991) Leukotriene blockers, novel therapeu-tic strategies for the treatment of asthma. Drug News Perspect 4: 264–271
Harper RW, Herron DK, Bollinger NG, Sawyer JS, Baldwin RF, Roman CR, Rinkema LE, Fleisch JH (1992) Development of a series of phenyltetrazole leukotriene D4 (LTD4) receptor antagonists. J Med Chem 35: 1191–1200
von Sprecher A, Beck A, Gerspacher M, Sallmann A, Anderson GP, Subramanian N, Niederhauser U, Bray MA (1993) Strategies in the design of peptidoleukotriene antagonists. J Lipid Mediators 6 (1–3): 265–273
von Sprecher A, Beck A, Sallmann A, Breitenstein W, Wiestner HR, Kimmel S, Anderson GP, Subramanian N, Bray MA (1991) Peptidoleukotricne antagonists: Structural analogs of leukotriene D4 with special emphasis on CGP 45715A. Drugs Future 19 (9): 827–843
von Sprecher A, Beck A, Sallmann A, Breitenstein W, Wiestner H, Brokatzky-Geiger J, Eisler K, Gamboni R, Rösslein L, Schlingloff G et al (1991) CGP 45715A, a potent peptidoleukotriene antagonist based on the structure of LTD4. Med Chem Res 1: 195–200
von Sprecher A, Beck A (Ciba-Geigy AG) Neue Alkanophenone. Eur Pat Appl EP 335–315
von Sprecher A, Ernest I, Main A, Beck A, Breitenstein W, Märki F, Bray MA (1987) Novel leukotriene antagonists: Structure activity of analogs of LTD4. Replacement of the 1-carboxylic group by a methyl group (“methyl principle”) results in leukotriene antagonists and phospholipase inhibitors. In: B Samuelsson, R Paoletti, PW Ramwell (eds): Advances in prostaglandin,thromboxane leukotriene research, vol 17. Raven Press, New York, 519–525
O’Byrne, Fuller RW (1989) The role of thromboxane A2 in the pathogenesis of airway hyperresponsiveness. Eur Resp J 2 (8): 782–786
Jones TR, Zamboni R, Belley M, Champion E, Charette L, Ford-Hutchinson AW, Gautier J-Y, Leger S, Lord A, Masson P et al (1992) Pharmacology of the leukotriene antagonist verlukast — The (R)-enantiomer of MK-571. Can J Physiol Pharmacol 69: 1847–1854
Metters KM, Zamboni RJ (1993) Photoaffinity labeling of the leukotriene D4 receptor in guinea pig lung. J Biol Chem 268: 6487–6495
Ahmed A, Cortes A, Sielczak MW, Abraham WM (1992) The effects of a leukotriene (LT) D4 receptor antagonist (CGP 45715A) on LTD4 and antigen-induced responses in allergic sheep. Am Rev Resp Dis 145: A288
Okudaira H (1997) Challenge studies of a leukotriene receptor antagonist. Chest 111 (Suppl 2): 46–51
Makker HK, Lau LC, Thomson HW, Brinks SM, Holgate ST (1993) The protective effect of inhaled leukotriene D4 receptor antagonist ICI 204,219 against exercise-induced asthma. Am Rev Respir Dis 147: 1413–1418
Hansen-Flaschen J, Schotland H (1998) New treatments for exercise-induced asthma. N Engl J Med 339 (3): 192–193
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1999 Springer Basel AG
About this chapter
Cite this chapter
Tittmann, U.P., Patalano, F., Ziehmer, B.A., von Sprecher, A., Bray, M.A. (1999). The development of iralukast: A member of the Novartis series of cysteinyl leukotriene antagonists. In: Folco, G., Samuelsson, B., Murphy, R.C. (eds) Novel Inhibitors of Leukotrienes. Progress in Inflammation Research. Birkhäuser, Basel. https://doi.org/10.1007/978-3-0348-8703-8_18
Download citation
DOI: https://doi.org/10.1007/978-3-0348-8703-8_18
Publisher Name: Birkhäuser, Basel
Print ISBN: 978-3-0348-9736-5
Online ISBN: 978-3-0348-8703-8
eBook Packages: Springer Book Archive